title: Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice.
abstract: The aim of this study was to evaluate the antileishmanial effects of topical liposomal paromomycin sulfate (PM) in Leishmania major-infected BALB/c mice. Liposomes containing 10 or 15% PM (Lip-PM-10 and Lip-PM-15, respectively) were prepared by the fusion method and were characterized for their size and encapsulation efficiency. The penetration of PM from the liposomal PM formulations (LPMFs) through and into skin was evaluated in vitro with Franz diffusion cells fitted with mouse skin at 37 degrees C for 8 h. The in vitro permeation data showed that almost 15% of the LPMFs applied penetrated the mouse skin, and the amount retained in the skin was about 60% for both formulations. The 50% effective doses of Lip-PM-10 and Lip-PM-15 against L. major promastigotes in culture were 65.32 and 59.73 microg/ml, respectively, and those against L. major amastigotes in macrophages were 24.64 and 26.44 microg/ml, respectively. Lip-PM-10 or Lip-PM-15 was used topically twice a day for 4 weeks to treat L. major lesions on BALB/c mice, and the results showed a significantly (P < 0.001) smaller lesion size in the mice in the treated groups than in the mice in the control group, which received either empty liposomes or phosphate-buffered saline (PBS). Eight weeks after the beginning of the treatment, every mouse treated with LPMFs was completely cured. The spleen parasite burden was significantly (P < 0.001) lower in mice treated with Lip-PM-10 or Lip-PM-15 than in mice treated with PBS or control liposomes, but no significant difference was seen between the two groups treated with either Lip-PM-10 or Lip-PM-15. The results suggest that topical liposomal PM may be useful for the treatment of cutaneous leishmaniasis.
authors.affiliation: School of Pharmacy, Biotechnology Research Center, Mashhad University of Medical Sciences, P.O. Box 91775-1365, Mashhad, Iran. jafarimr@mums.ac.ir
authors.forename: Mahmoud R
authors.initials: MR
authors.lastname: Jaafari
authors.forename: Neda
authors.initials: N
authors.lastname: Bavarsad
authors.forename: Bibi Sedigheh Fazly
authors.initials: BS
authors.lastname: Bazzaz
authors.forename: Afshin
authors.initials: A
authors.lastname: Samiei
authors.forename: Dina
authors.initials: D
authors.lastname: Soroush
authors.forename: Serajodin
authors.initials: S
authors.lastname: Ghorbani
authors.forename: Mohammad M Lotfi
authors.initials: MM
authors.lastname: Heravi
authors.forename: Ali
authors.initials: A
authors.lastname: Khamesipour
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D002460:Cell Line; D004058:Diffusion; D005260:Female; D018320:Leishmania major; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008081:Liposomes; D051379:Mice; D008807:Mice, Inbred BALB C; D010303:Paromomycin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D010316:Particle Size; D012867:Skin / Q000378:metabolism; D013154:Spleen / Q000469:parasitology
chemical_list: D008081:Liposomes; D010303:Paromomycin